Enhanced Antitumor Efficacy of Vasculostatin (Vstat120) Expressing Oncolytic HSV-1

• Published in: Molecular therapy Vol. 18; no. 2; pp. 285 - 294
• Main Authors: Hardcastle, Jayson, Kurozumi, Kazuhiko, Dmitrieva, Nina, Sayers, Martin P, Ahmad, Sarwat, Waterman, Peter, Weissleder, Ralph, Chiocca, E Antonio, Kaur, Balveen
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2010; Elsevier Limited; Nature Publishing Group
• Subjects: Amino acids; Angiogenesis; Angiogenic Proteins - genetics; Angiogenic Proteins - physiology; Animals; Blotting, Western; Brain cancer; Brain research; Cancer therapies; Cell Line; Cell Line, Tumor; Cercopithecus aethiops; Glioma - metabolism; Glioma - pathology; Glioma - therapy; Herpes viruses; Humans; Infections; Mice; Mice, Nude; Neurosciences; Oncology; Oncolytic Viruses - genetics; Oncolytic Viruses - physiology; Original; Simplexvirus - genetics; Surgery; Tumors; Vero Cells; United States > US; Massachusetts; Ohio
• ISSN: 1525-0016; 1525-0024
• DOI: 10.1038/mt.2009.232

Oncolytic viral (OV) therapy is a promising therapeutic modality for brain tumors. Vasculostatin (Vstat120) is the cleaved and secreted extracellular fragment of brain-specific angiogenesis inhibitor 1 (BAI1), a brain-specific receptor. To date, the therapeutic efficacy of Vstat120 delivery into established tumors has not been investigated. Here we tested the therapeutic efficacy of combining Vstat120 gene delivery in conjunction with OV therapy. We constructed RAMBO (Rapid Antiangiogenesis Mediated By Oncolytic virus), which expresses Vstat120 under the control of the herpes simplex virus (HSV) IE4/5 promoter. Secreted Vstat120 was detected as soon as 4 hours postinfection in vitro and was retained for up to 13 days after OV therapy in subcutaneous tumors. RAMBO-produced Vstat120 efficiently inhibited endothelial cell migration and tube formation in vitro (P = 0.0005 and P = 0.0184, respectively) and inhibited angiogenesis (P = 0.007) in vivo. There was a significant suppression of intracranial and subcutaneous glioma growth in mice treated with RAMBO compared to the control virus, HSVQ (P = 0.0021 and P < 0.05, respectively). Statistically significant reduction in tumor vascular volume fraction (VVF) and microvessel density (MVD) was observed in tumors treated with RAMBO. This is the first study to report the antitumor effects of Vstat120 delivery into established tumors and supports the further development of RAMBO as a possible cancer therapy.